Kymera Therapeutics will participate in investor conferences on February 6 and 11, featuring live webcasts of presentations.
Quiver AI Summary
Kymera Therapeutics, Inc. announced its participation in two upcoming investor events: the Guggenheim SMID Cap Biotechnology Conference on February 6 and the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11. The company focuses on developing oral small molecule degrader medicines for immunological diseases, leveraging its expertise in targeted protein degradation (TPD). Live webcasts of the presentations will be available on Kymera’s website, with replays offered afterward. Founded in 2016, Kymera has gained recognition as a leading workplace in Boston and aims to create effective therapies for challenging health conditions.
Potential Positives
- Kymera Therapeutics is actively engaging with investors by participating in notable industry conferences, which can enhance visibility and credibility in the market.
- The company is pioneering targeted protein degradation (TPD), indicating a strong innovative position in developing new therapies for immunological diseases.
- Kymera has already advanced its first degrader into clinical use, demonstrating progress in its drug development pipeline.
- The company's recognition as one of Boston’s top workplaces reflects a positive organizational culture, which can attract talent and enhance its reputation.
Potential Negatives
- Participation in investor events may indicate a need for increased investor engagement, suggesting potential concerns about investor confidence or company performance.
FAQ
What upcoming investor events is Kymera Therapeutics participating in?
Kymera Therapeutics will participate in the Guggenheim SMID Cap Biotechnology Conference on February 6 and the Oppenheimer 35th Annual Healthcare Conference on February 11.
How can I access the presentations from Kymera Therapeutics?
Live webcasts of the presentations will be available on the Company's website under “News and Events” in the Investors section.
What is the focus of Kymera Therapeutics?
Kymera Therapeutics focuses on developing oral small molecule degrader medicines for immunological diseases using targeted protein degradation technology.
When was Kymera Therapeutics founded?
Kymera Therapeutics was founded in 2016 and has been recognized as one of Boston’s top workplaces for several years.
How can I contact Kymera Therapeutics for investor inquiries?
Interested investors can contact Justine Koenigsberg at investors@kymeratx.com for inquiries related to investments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KYMR Insider Trading Activity
$KYMR insiders have traded $KYMR stock on the open market 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $KYMR stock by insiders over the last 6 months:
- PAMELA ESPOSITO has made 0 purchases and 3 sales selling 16,000 shares for an estimated $774,265.
- JEFFREY W. ALBERS sold 5,000 shares for an estimated $245,508
- ELLEN CHINIARA (Chief Legal Officer) sold 3,129 shares for an estimated $130,644
- BROS. ADVISORS LP BAKER purchased 1 shares for an estimated $46
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KYMR Hedge Fund Activity
We have seen 84 institutional investors add shares of $KYMR stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARTAL GROUP S.A. removed 3,005,610 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $142,255,521
- DRIEHAUS CAPITAL MANAGEMENT LLC added 1,105,290 shares (+494.7%) to their portfolio in Q3 2024, for an estimated $52,313,375
- DEEP TRACK CAPITAL, LP removed 899,674 shares (-60.0%) from their portfolio in Q3 2024, for an estimated $42,581,570
- AVORO CAPITAL ADVISORS LLC added 611,112 shares (+15.7%) to their portfolio in Q3 2024, for an estimated $28,923,930
- AVIDITY PARTNERS MANAGEMENT LP added 500,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $23,665,000
- ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC removed 453,960 shares (-8.5%) from their portfolio in Q3 2024, for an estimated $21,485,926
- BOXER CAPITAL, LLC added 450,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $21,298,500
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) --
Kymera Therapeutics, Inc.
(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:
Guggenheim SMID Cap Biotechnology Conference in New York, NY on February 6 at 10:00 a.m. ET; and
Oppenheimer 35
th
Annual Healthcare Life Sciences Conference held virtually on February 11 at 11:20 a.m. ET.
Live webcasts of the presentations will be available under “
News and Events
” in the Investors section of the Company’s website at
www.kymeratx.com
. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit
www.kymeratx.com
or follow us on
X
or
LinkedIn
.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
